-
Join 20 other subscribers
Categories
- ADME
- Bioactivation
- Biotransformation
- Blood Brain Barrier
- Carcinogens
- Central Nervous System (CNS)
- Chemistry
- Company
- Conjugation Reactions
- Covalent Binding
- Cytochrome P450
- Definitions
- Disease
- DNA Adducts
- Drug Design
- Drug Drug Interaction (DDI)
- Drug Metabolism
- Drug Safety
- Drug Target
- Drugs
- Heterocycles
- Human Liver Microsomes(HLM)
- Idiosyncratic Effect
- Immune Response
- In Vitro/In Vivo Correlation
- Introduction
- Mass Spectrometry
- Mechanism-Based Inhibition (MBI)
- Med Chem
- Metabolic Stability
- Metabolite Identification (MetID)
- Metabolite Prediction
- Metabolite Profiling
- Metabolomics
- Mutagens
- Natrual Products
- Non-P450 enzymes
- P450 Phenotyping
- Pharmacokinetics (PK)
- Phase 2 Metabolism
- Physicochemical Properties
- Protein Adducts
- Radioisotope Label
- Reactive Intermediates
- SAR
- Solvent Effects
- Time-dependent Inhibition (TDI)
- Toxicity
- Uncategorized
Recently Viewed Posts
- Metabolically Stable tert-Butyl Replacement ACS Med Chem Lett 2013
- Deuterated Clopidogrel Analogues as a New Generation of Antiplatelet Agents ACS Med Chem Lett 2013
- Thiolactone Sulfoxides as New Reactive Metabolites Acting as Bis-Electrophiles: Implication in Clopidogrel and Prasugrel Bioactivation CRT 2013
- Which Metabolites Circulate? Minireview DMD 2013
- Boronic Acid-Containing Proteasome Inhibitors: Alert to Potential Pharmaceutical Bioactivation CRT 2013
Blogs I Follow
Daily Archives: October 25, 2012
Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds from GSK CRT 2012
Sakatis, M. Z., et al. Chem. Res. Toxicol., 2012, 25 (10), pp 2067–2082 In this study, 223 marketed drugs (51% associated with clinical hepatotoxicity; 49% non-hepatotoxic) were examined to assess the concordance of in vitro bioactivation data with clinical hepatotoxicity. By using a decision tree developed from … Continue reading
Use of Radiolabeled Compounds in Drug Metabolism and Pharmacokinetic Studies from AstraZeneca CRT 2012
Isin, E. M., et al. Chem. Res. Toxicol., 2012, 25 (3), pp 532–542 A brief overview of DMPK studies involving radiolabeled compounds at AstraZeneca Common approaches for the preparation of 14C- and 3H-labeled drug candidates were described in this paper.
ADMETchemist 